From registration to commercialization, the KYE team creatively addresses the challenges of the Canadian pharmaceutical environment to bring important new medicines to our market as quickly and economically as possible.

With more than 30 years of commercial experience in the Canadian pharmaceutical industry, Doug has held roles at several large multinational companies such as Lederle Laboratories, Syntex Inc., Hoffmann-La Roche, Sanofi Inc. In 2001, he founded, and led as President, Oryx Pharmaceuticals Inc., a Canadian-based specialty pharmaceutical company. Under Doug’s leadership Oryx grew rapidly and was acquired by Sepracor Inc. in 2008 (later acquired and renamed Sunovion). Doug remained as President of Sunovion Canada from 2008 to 2019, and Sunovion tripled its Canadian sales during his tenure. Doug founded Kye Pharmaceuticals in 2019 and is currently Chairman of the Board.

Craig brings 20 years of pharmaceutical industry leadership and business development experience. Prior to co-founding Juno in 2011, Craig worked for Cobalt Pharmaceuticals, where he was responsible for negotiating OTC and generic license and supply agreements, as well as leading all global M&A transactions. Currently, a partner at C-Point Capital and Juno LP., Craig selectively invests in and acquires pharmaceutical and medical device companies in Canada, Europe, South Africa and Australia. He serves on the Board of Directors for several healthcare companies in Canada and internationally.

As founder & CEO of Tris Pharma, Ketan has developed innovative technologies, new products, and built Tris as a leader among emerging, CNS-focused pharmaceutical companies. Prior to founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing, and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.

Graham brings 30 years of experience in the UK pharmaceutical industry. Beginning with leadership roles at Allen & Hanbury’s (now GSK) and Dominion, Graham was promoted to Managing Director at Pliva and spearheaded a 6-fold increase in the annual turnover for Pliva UK over the subsequent 10 years, making Pliva a leading supplier of ethical medicines to the NHS. Graham set up Aspire Pharma in June 2009, subsequently building Aspire into one of the fastest growing pharmaceutical companies in the UK.

Ian has over 35 years of pharmaceutical industry experience. Prior to co-founding CPOINT Capital, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, responsible for managing over $300 million in annual sales. Ian played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive VP, and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.